The Senate Finance Committee today held a hearing for Alex Azar, President Trump’s nominee for secretary of Health and Human Services. Azar, former president of Lilly USA and deputy HHS secretary under the George W. Bush administration, faced a number of questions from senators about his ties to the pharmaceutical industry and how he would tackle high drug prices. If confirmed, Azar said he would focus his efforts on addressing the high cost of drugs; making health care more affordable, available and “tailored to what individuals want and need in their care”; harnessing “the power of Medicare to shift the focus in our health care system from paying for procedures and sickness to paying for health and outcomes”; and tackling “the scourge of the opioid epidemic.” Tom Price, M.D., resigned as HHS secretary last September. Deputy Secretary Eric Hargan has been serving as acting secretary.

Related News Articles

Headline
In continuing recognition of Mental Health Awareness Month, Azziza Bankole, M.D., writes about the negative effects of social isolation and loneliness and how…
Blog
Exploring and developing a better understanding of the social determinants of health is becoming standard in medical education and training. Social isolation…
Headline
The Centers for Medicare & Medicaid Services May 9 announced an extension of unwinding flexibilities to support state efforts to protect the continuity of…
Perspective
Hospitals hold an extraordinary place in our society by offering comfort and caring to all who walk through their doors, regardless of ability to pay.While the…
Headline
Two experts from AdventHealth discuss how its “Be a Mindleader” campaign is leading the way to improving adolescent mental health by helping parents and kids…
Headline
The Centers for Medicare & Medicaid Services May 3 announced the opening of the comment period for the Inflation Reduction Act’s Medicare Drug Price…